Imaging Metformin Efficacy as Add-On Therapy in Cells and Mouse Models of Human EGFR Glioblastoma

Imaging Metformin Efficacy as Add-On Therapy in Cells and Mouse Models of Human EGFR Glioblastoma

Glioblastoma (GBM) is a highly aggressive tumor of the brain. Despite the efforts, response to current therapies is poor and 2-years survival rate ranging from 6-12%. Here, we evaluated the preclinical efficacy of Metformin (MET) as add-on therapy to Temozolomide (TMZ) and the ability of [18F]FLT (a...

Full description

Bibliographic Details
Main Authors: Silvia Valtorta, Alessia Lo Dico, Isabella Raccagni, Cristina Martelli, Valentina Pieri, Paolo Rainone, Sergio Todde, Bastian Zinnhardt, Elisabetta De Bernardi, Angela Coliva, Letterio S. Politi, Thomas Viel, Andreas H. Jacobs, Rossella Galli, Luisa Ottobrini, Valentina Vaira, Rosa Maria Moresco
Format: Article
Language:English
Published: Frontiers Media S.A. 2021-05-01
Series:Frontiers in Oncology
Subjects:
GBM - glioblastoma multiforme
metformin
inflammation
PET imaging
[18F]FLT
EGFR - epidermal growth factor receptor
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2021.664149/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2021.664149/full

Similar Items